Superworth

BlossomHill Therapeutics BLSM

Drug Manufacturers - General, Healthcare
$14.63
−7.46%
Market cap
$465M
PE
n/m
one or more of the four quarters through 2026-06-30 missing
Forward PE
n/m
not a meaningful number
Price to sales
n/m
not a meaningful number
EV/EBIT
n/m
not a meaningful number
Revenue, 12 months
n/m
not a meaningful number
Net margin
n/m
not a meaningful number
Free cash flow yield
n/m
not a meaningful number

Charts

Financials

Income statement for BLSM, by quarter
Income statementQ1 FY25Q2 FY25Q1 FY26Q2 FY26
R&D$9.6M$12.5M$19.9M$21.4M
SG&A$1.9M$1.6M$2.2M$3.3M
−$11.5M−$14.1M−$22.1M−$24.7M
Net income−$10.5M−$13.2M−$21M−$23.8M
−$4.39−$5.51−$8.15−$8.75
2.4M2.4M2.6M2.7M

R&D: Q1 FY25 and Q1 FY26: 6 months less the 3 months printed beside them.

SG&A: Q1 FY25 and Q1 FY26: 6 months less the 3 months printed beside them.

Operating income: Q1 FY25 and Q1 FY26: 6 months less the 3 months printed beside them.

Net income: Q1 FY25 and Q1 FY26: 6 months less the 3 months printed beside them.

EPS, diluted: Q1 FY25 and Q1 FY26: quarter's net income to common over its shares, to the cent.

Diluted shares: Q1 FY25 and Q1 FY26: share-days: the 6-month average less the second quarter's.

From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.

Peers

Companies in Drug Manufacturers - General nearest BlossomHill Therapeutics' size, closest first.

CompanyMarket capPEIts 10y median PEFwd PEP/SRevenue growthNet margin
BLSMBlossomHill Therapeutics$465Mn/mn/an/mn/mn/m
ARVNArvinas$477.3M45.6×52.3×1.5×−15%2.9%
PBYIPuma Biotechnology$568.9M21.2×12.3×2.5×−3%11.6%
IRWDIronwood Pharmaceuticals$571.7M4.5×14.9×1.5×+26%33.4%
ZVRAZevra Therapeutics$582.6M10.5×12.3×4.3×+119%42.8%
CRMDCorMedix$611.9M3.7×4.0×1.3×+281%40.5%
COLLCollegium Pharmaceutical$747.5M18.5×19.1×0.9×+14%5.9%
ABUSArbutus Biopharma$831M5.4×5.6×4.6×n/m84.2%
NATRNatures Sunshine Products$213.8M12.0×20.6×0.4×+7%3.7%
AMPHAmphastar Pharmaceuticals$1.1B14.8×20.6×1.5×+1%10.8%
OMEROmeros$1.2B10.9×11.7×n/mn/mn/m
Peer median$597.2M11.5×13.6×1.5×+11%11.6%

More on BlossomHill Therapeutics

Each number over time

Its groups

About

Industry
Drug Manufacturers - General
Sector
Healthcare

Valuation data, not investment advice. Prices as of .